

## **Zaltrap**

## **CareFirst Prior Authorization Request**

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-855-330-1720**. If you have questions regarding the prior authorization, please contact CVS Caremark at **1-888-877-0518**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do\_not\_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name:	Date:
Patient's ID:	
Physician's Name:	
Specialty:	
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info: ☐ Same as Re	equesting Provider
Name:	NPI#:
Fax:	Phone:
<b>Rendering Provider Info:</b> □ Same as Rendering Provider Info: □ Same as Rendering Pro	eferring Provider □ Same as Requesting Provider
Name:	NPI#:
Fax:	Phone:  t to dosing limits in accordance with FDA-approved labeling,
Fax:Approvals may be subject accepted comp	Phone:
Fax:Approvals may be subject accepted comp	Phone:  t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines.
Fax:  Approvals may be subject accepted comp  Required Demographic Information:	Phone:  t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines. kg
Fax:  Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the	Phone:  t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines. kgcm
Fax:  Approvals may be subject accepted comp  Required Demographic Information:  Patient Weight:  Patient Height:  Please indicate the place of service for the	Phone:  t to dosing limits in accordance with FDA-approved labeling, pendia, and/or evidence-based practice guidelines. kgcm

<u>Criteria Questions:</u>	
1. What is the diagnosis?	
☐ Colorectal cancer (CRC), including anal adenocarcinoma and appendiceal adenocarcinoma, <i>Continue to 2</i>	
☐ Other, please specify, Continue to 2	
<ul> <li>2. Is the patient currently receiving treatment with the requested medication?</li> <li>☐ Yes, Continue to 3</li> <li>☐ No, Continue to 4</li> </ul>	
3. Has the patient experienced disease progression or an unacceptable toxicity while on the current regimen? ☐ Yes, <i>No Further Questions</i> ☐ No, <i>No Further Questions</i>	
4. What is the clinical setting in which the requested medication will be used?	
☐ Advanced disease, <i>Continue to 5</i>	
☐ Metastatic disease, <i>Continue to 5</i>	
☐ Other, please specify, Continue to 5	
5. What will be the prescribed regimen?  The requested medication in combination with 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI), <i>No further questions</i> The requested medication in combination with irinotecan. <i>No further questions</i>	
☐ The requested medication in combination with irinotecan, <i>No further questions</i> ☐ Other, please specify, <i>No further questions</i>	
I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.	
X	